<DOC>
	<DOCNO>NCT00161187</DOCNO>
	<brief_summary>RATIONALE : When irradiate lymphocyte donor infused patient may help patient 's immune system kill cancer cell . PURPOSE : This pilot study look side effect well irradiate donor lymphocyte infusion work treat patient relapsed refractory hematologic cancer solid tumor .</brief_summary>
	<brief_title>Irradiated Donor Lymphocyte Infusion Treating Patients With Relapsed Refractory Hematologic Cancer Solid Tumor</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity irradiate allogeneic donor lymphocyte infusion patient relapse refractory hematological cancer solid tumor . - Determine response patient treat regimen . - Determine presence disease antigen-specific lymphocytes patient treated regimen . OUTLINE : This pilot , open-label , control study . Patients undergo irradiated allogeneic donor lymphocyte infusion 1 hour day 1 . Treatment repeat every 8-16 week 6 infusion absence disease progression unacceptable toxicity . Blood sample collect periodically analyze lymphocytotoxicity direct towards patient ' cell ( normal malignant cell ) disease antigen-specific cell . Samples also analyze survival donor lymphocytes chimerism study . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis 1 following : Hematologic cancer , include follow : Chronic lymphocytic leukemia small lymphocytic lymphoma meeting follow criterion : Relapsed within 1 year prior fludarabine phosphatecontaining regimen OR candidate receive therapy due comorbidities allergy Received prior antiCD52 monoclonal antibody therapy OR ineligible receive therapy ( patient without symptomatic lymphadenopathy ) Has documentation diseaseassociated symptom , rapid progression disease , indication treatment B Tcell prolymphocytic leukemia meeting follow criterion : Relapsed within 1 year prior fludarabine phosphate alkylating agentcontaining regimen OR candidate receive therapy due comorbidities allergy Relapsed within 1 year prior antiCD20 monoclonal antibody therapy OR ineligible receive therapy ( patient CD20positive disease ) Received prior antiCD52 monoclonal antibody therapy OR ineligible receive therapy ( patient without symptomatic lymphadenopathy ) Lymphoplasmacytic lymphoma , marginal zone lymphoma , mucosaassociated lymphoid tissue lymphoma , follicular lymphoma meeting follow criterion : Relapsed within 1 year prior fludarabine phosphate alkylating agentcontaining regimen radioconjugated antiCD20 monoclonal antibody OR candidate receive therapy due comorbidities allergy Relapsed within 1 year prior antiCD20 monoclonal antibody therapy OR ineligible receive therapy ( patient CD20positive disease ) Has documentation diseaseassociated symptom , rapid progression disease , indication treatment Multiple myeloma meeting follow criterion : Relapsed prior alkylating agent , thalidomide , corticosteroid , bortezomib OR candidate receive therapy due comorbidities allergy Relapsed prior highdose chemotherapy follow autologous hematopoietic stem cell rescue OR candidate receive therapy Mantle cell lymphoma relapse prior combination chemotherapy antiCD20 monoclonal antibody OR candidate receive therapy Diffuse large Bcell lymphoma meeting follow criterion : Relapsed prior salvage combination chemotherapy without highdose chemotherapy follow autologous hematopoietic stem cell rescue OR candidate receive therapy Received prior radiolabeled antiCD20 monoclonal antibody OR ineligible receive therapy ( patient transform large cell lymphoma ) Burkitt 's lymphoma Relapsed prior salvage combination chemotherapy without highdose chemotherapy follow autologous hematopoietic stem cell rescue OR candidate therapy Lymphomatoid granulomatosis mature Tcell NKcell neoplasms meet follow criterion : Relapsed prior single agent combination chemotherapy OR candidate receive therapy Has documentation diseaseassociated symptom , rapid progression disease , indication treatment Mycosis fungoides Sezary syndrome Relapsed prior combination chemotherapy , interferonα , denileukin diftitox , extracorporeal photophoresis OR candidate receive therapy Anaplastic large cell lymphoma , peripheral Tcell lymphoma unspecified , angioimmunoblastic Tcell lymphoma meeting follow criterion : Relapsed prior salvage combination chemotherapy without highdose chemotherapy follow autologous hematopoietic stem cell rescue OR candidate receive therapy Hepatosplenic Tcell lymphoma adult Tcell leukemia/lymphoma Relapsed prior salvage combination chemotherapy OR candidate receive therapy Hodgkin 's lymphoma Relapsed prior salvage combination chemotherapy without highdose chemotherapy follow autologous hematopoietic stem cell rescue OR candidate receive therapy Acute lymphocytic leukemia meeting follow criterion : Relapsed prior multiagent combination chemotherapy administer sequential induction , consolidation , maintenance course OR candidate receive therapy Relapsed prior salvage combination chemotherapy without highdose chemotherapy follow autologous hematopoietic stem cell rescue OR candidate receive therapy Relapsed prior chemotherapy without radiotherapy follow allogeneic hematopoietic stem cell transplant ( ineligible therapy ) AND demonstrate persistent cytogenetic , fluorescent situ hybridization ( FISH ) , molecular ( reverse transcriptasepolymerase chain reaction ) evidence bcrabl fusion gene despite 6 week treatment imatinib mesylate Acute myelogenous leukemia myelodysplasia meeting follow criterion : Relapsed refractory disease prior induction chemotherapy ( anthracycline cytarabine , topotecan hydrochloride cytarabine , comparable regimen ) OR candidate receive therapy Not candidate chemotherapy without radiotherapy follow allogeneic autologous hematopoietic stem cell transplant Patients acute promyelomonocytic leukemia must receive prior tretinoin arsenic trioxide Chronic myelogenous leukemia meeting follow criterion : Relapsed refractory disease prior imatinib mesylate Not candidate chemotherapy without radiotherapy follow allogeneic hematopoietic stem cell transplant Chronic phase disease allow FISH cytogenetic evidence increase disease Solid tumor , include follow : Renal cell carcinoma Metastatic relapse refractory disease prior highdose aldesleukin OR ineligible receive therapy due comorbidities OR consent treatment Bladder cancer gastric cancer Metastatic relapse refractory disease prior combination therapy OR candidate receive therapy Prostate cancer Metastatic relapse refractory disease prior hormonal therapy OR candidate receive therapy Testicular cancer Metastatic relapse refractory disease prior standard induction salvage chemotherapy highdose chemotherapy autologous hematopoietic stem cell rescue OR candidate receive therapy Pancreatic cancer Metastatic relapse refractory disease prior gemcitabine hydrochloridebased therapy OR candidate receive therapy Hepatocellular carcinoma Unresectable metastatic disease Colorectal carcinoma Metastatic relapse refractory disease prior combination therapy , include fluorouracil without leucovorin calcium , oxaliplatin , irinotecan hydrochloride OR candidate receive therapy Breast cancer meeting follow criterion : Metastatic relapse refractory disease prior first secondline standard combination chemotherapy OR candidate receive therapy Received prior trastuzumab ( Herceptin® ) sequential hormonal therapy OR candidate receive therapy indicate biological characteristic cancer Lung cancer ( nonsmall cell small cell lung cancer ) , ovarian cancer , endometrial cancer , cervical cancer Metastatic relapse refractory disease prior first secondline combination chemotherapy OR candidate receive therapy Malignant melanoma Metastatic relapse refractory disease prior immunotherapy combination chemotherapy OR candidate receive therapy Sarcoma meeting follow criterion : Metastatic relapse refractory disease prior first secondline combination chemotherapy OR candidate receive therapy Not candidate resection Patients gastrointestinal stromal tumor must receive prior imatinib mesylate Measurable disease Must receive prior available standard therapy specific disease OR candidate treatment No CNS malignancy HLApartially match ( ≥ 2/6 HLA antigen [ A , B , DR ] ) relate donor ( 18 year age ) available PATIENT CHARACTERISTICS : ECOG performance status 01 Life expectancy &gt; 3 month Bilirubin &lt; 1.5 time upper limit normal ( ULN ) AST &lt; 3.0 time ULN LVEF &gt; 35 % No active infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No uncontrolled medical psychiatric illness would preclude study compliance , opinion investigator PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>childhood diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>recurrent bladder cancer</keyword>
	<keyword>stage IV bladder cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent malignant testicular germ cell tumor</keyword>
	<keyword>stage III malignant testicular germ cell tumor</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>recurrent childhood liver cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>recurrent cervical cancer</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
	<keyword>chondrosarcoma</keyword>
	<keyword>recurrent osteosarcoma</keyword>
	<keyword>previously treat childhood rhabdomyosarcoma</keyword>
	<keyword>recurrent childhood rhabdomyosarcoma</keyword>
	<keyword>ovarian sarcoma</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>stage I childhood large cell lymphoma</keyword>
	<keyword>stage II childhood large cell lymphoma</keyword>
	<keyword>stage III childhood large cell lymphoma</keyword>
	<keyword>stage IV childhood large cell lymphoma</keyword>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>ovarian stromal cancer</keyword>
	<keyword>stage IA cervical cancer</keyword>
	<keyword>stage IB cervical cancer</keyword>
	<keyword>stage IIA cervical cancer</keyword>
	<keyword>stage IIB cervical cancer</keyword>
	<keyword>stage III cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
	<keyword>stage IVB cervical cancer</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent endometrial carcinoma</keyword>
	<keyword>stage I endometrial carcinoma</keyword>
	<keyword>stage II endometrial carcinoma</keyword>
	<keyword>stage III endometrial carcinoma</keyword>
	<keyword>stage IV endometrial carcinoma</keyword>
	<keyword>childhood hepatocellular carcinoma</keyword>
	<keyword>stage III childhood liver cancer</keyword>
	<keyword>stage IV childhood liver cancer</keyword>
	<keyword>previously untreated childhood rhabdomyosarcoma</keyword>
	<keyword>metastatic childhood soft tissue sarcoma</keyword>
	<keyword>localize Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>stage I grade 1 follicular lymphoma</keyword>
	<keyword>stage I grade 2 follicular lymphoma</keyword>
	<keyword>stage I grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>localize osteosarcoma</keyword>
	<keyword>metastatic osteosarcoma</keyword>
	<keyword>stage I ovarian epithelial cancer</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
	<keyword>stage I ovarian germ cell tumor</keyword>
	<keyword>stage II ovarian germ cell tumor</keyword>
	<keyword>stage III ovarian germ cell tumor</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
	<keyword>limited stage small cell lung cancer</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage II malignant testicular germ cell tumor</keyword>
	<keyword>stage I adult soft tissue sarcoma</keyword>
	<keyword>stage II adult soft tissue sarcoma</keyword>
	<keyword>stage III adult soft tissue sarcoma</keyword>
	<keyword>stage I bladder cancer</keyword>
	<keyword>stage II bladder cancer</keyword>
	<keyword>stage III bladder cancer</keyword>
	<keyword>male breast cancer</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage I colon cancer</keyword>
	<keyword>stage II colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage I gastric cancer</keyword>
	<keyword>stage II gastric cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage I pancreatic cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage II prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage I rectal cancer</keyword>
	<keyword>stage II rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage I renal cell cancer</keyword>
	<keyword>stage II renal cell cancer</keyword>
	<keyword>stage III renal cell cancer</keyword>
	<keyword>stage I uterine sarcoma</keyword>
	<keyword>stage II uterine sarcoma</keyword>
	<keyword>stage III uterine sarcoma</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>untreated childhood acute myeloid leukemia myeloid malignancy</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>nonmetastatic childhood soft tissue sarcoma</keyword>
	<keyword>recurrent childhood soft tissue sarcoma</keyword>
	<keyword>stage I childhood Hodgkin lymphoma</keyword>
	<keyword>stage II childhood Hodgkin lymphoma</keyword>
	<keyword>stage III childhood Hodgkin lymphoma</keyword>
	<keyword>stage IV childhood Hodgkin lymphoma</keyword>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage I childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage II childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage III childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
	<keyword>Burkitt lymphoma</keyword>
	<keyword>stage I adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage II adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage I malignant testicular germ cell tumor</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
	<keyword>childhood renal cell carcinoma</keyword>
	<keyword>stage IA melanoma</keyword>
	<keyword>stage IB melanoma</keyword>
	<keyword>stage IIA melanoma</keyword>
	<keyword>stage IIB melanoma</keyword>
	<keyword>stage IIC melanoma</keyword>
	<keyword>stage IIIA melanoma</keyword>
	<keyword>stage IIIB melanoma</keyword>
	<keyword>stage IIIC melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>